ALT
Altimmune Inc
3.30$
+0.6%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -83.2% | -30.2% | 3,852.8% | -48,705.1% | -90.9% | -165.5% | -420.7% | -1,774.1% | – | -17,795.8% | -399,240.0% | -164,719.5% | |
| 1.5% | 1.3% | 2.7% | 335.0% | 2.9% | 6.7% | 3.6% | 12.5% | – | 112.0% | 1,190.0% | 273.2% | |
| 16.2% | 5.8% | 42.8% | 3,478.0% | 7.5% | 21.8% | 31.5% | 125.1% | – | 2,497.7% | 71,965.0% | 39,209.8% | |
| 12.6% | 3.0% | 62.6% | 83,523.9% | 188.2% | 150.2% | 230.0% | 420.7% | – | – | – | – | |
| 0.4% | -4.7% | 80.3% | -27,245.6% | 67.6% | 31.4% | -55.1% | -5.7% | – | -1,942.3% | 22,390.0% | 16,468.3% | |
| 0.9% | 0.8% | 0.6% | 400.8% | 9.8% | 0.5% | 4.2% | 279.2% | – | 11.0% | 0.0% | 26.8% | |
| -0.8% | -0.7% | -1,278.7% | 33,071.9% | -9.7% | -487.6% | -880.8% | 1,984.6% | – | 3,223.5% | -141,930.0% | -323,104.9% | |
| 0.0% | 0.0% | 0.0% | 0.0% | 0.2% | 65,354.6% | 1,655.1% | – | – | – | – | – | |
| 184.7% | 9.1% | 72.7% | 31,407.4% | -23.1% | 65,354.6% | 1,655.1% | 5,090.1% | – | 50.5% | 1,500.0% | 709.8% | |
| -20.5% | -7.0% | -1.5% | 6,761.8% | -15.0% | -5.0% | – | 0.0% | – | – | 0.0% | 85,365.9% | |
| 164.2% | 2.1% | 72.7% | 38,169.2% | 314.5% | 216.0% | 2,608.3% | 1,476.1% | – | 20,212.4% | 50,220.0% | 504,492.7% | |
| 80.1% | -28.9% | 2,646.7% | 22,715.3% | 213.4% | -437.1% | 1,306.7% | 1,686.7% | – | 5,640.1% | -490,950.0% | 16,668.3% | |
| -84.1% | -31.0% | 3,852.2% | -49,105.9% | -100.7% | -166.0% | -424.9% | -2,053.3% | – | -17,806.8% | -399,240.0% | -164,746.3% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.